drugset / Trial / NCT02434939

Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers

NCT02434939 ↗

Phase 4 Completed 240 enrolled Makerere University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical trial will inform of the role of Low dose ketamine in the acute treatment of severe painful sickle cell crisis in children in a day-case sickle cell centre. The primary aim is to determine whether Low dose ketamine is non inferior to morphine in the management of acute painful sickle cell crises. The specific objectives will be to determine the maximal change in NRS pain score following administration of ketamine and to examine the safety profile of ketamine compared to morphine in this population. The investigators hypothesize that low dose ketamine will result in similar effective pain control as morphine alone and will not be associated with an increase in adverse events.

Timeline

Start
2015-06
Primary completion
2016-01
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 1 mg/kg Intravenous
Comparator Morphine Other / unclassified 0.1 mg/kg Intravenous

Indications